ClinicalTrials.gg
RecruitingNCT07227896PUCCINIUpdated Nov 10, 2026

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

An observational study in Parkinson's Disease, sponsored by AbbVie. Recruiting at 26 sites in 9 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 10, 2026First sites in 5 new countriesSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.

Planned enrollment
13th of 18
100 · median 131
Started
2026
with 1 other
Observational
18 of 44
5 open now
Registered
42nd of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 13th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2026, is one of 18 observational ones, and was the 42nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.

There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Foslevodopa/Foscarbidopa
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
  • A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
  • Adult male or female between 18 and 69 years of age
  • Disease duration (time since diagnosis) \<10 years
  • Time since motor fluctuations started ≤5 years
  • H\&Y Stage \<3 in best "on"
  • "off" time of ≤ 4.5 hours per day
  • Naïve to LDp/CDp
  • Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
  • Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
  • Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
  • Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/ Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered

Exclusion criteria

Exclusion Criteria:

  • History of any condition included in the section of the approved local Foslevodopa/Foscarbidopa (LDp/CDp) label in the participating country
  • History of treatment with any Device-Aided Therapy (DAT), such as Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa/Carbidopa Intestinal Gel (LCIG)/ Carbidopa/Levodopa Enteral Suspension (CLES), Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG)
  • (MMSE) score \<24
  • Participation in a concurrent or observational clinical trial
  • Lack of motivation/insufficient language skills to complete the study questionnaires
  • History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis). In case of temporary affections like recent sunburn or open wounds, or in case of permanent affections like acne, scar tissue, tattoo, branding, or colorations, the participant should not be included if the Investigator considers these as interfering with infusion of study drug or study assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • Foslevodopa/Foscarbidopa

    Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

    Time frame: Up to approximately 6 months

Secondary outcomes

  1. Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

    Time frame: Up to approximately 6 months

  2. Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score

    The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

    Time frame: Up to approximately 6 months

  3. Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

    Time frame: Up to approximately 6 months

  4. Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index

    The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

    Time frame: Up to approximately 6 months

  5. Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)

    The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening.

    Time frame: Up to approximately 6 months

  6. Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

    Time frame: Up to approximately 6 months

  7. Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score

    The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\] with the exception of Question 1 score ranging from 0 \[very often\] to 4 \[never\]).

    Time frame: Up to approximately 6 months

  8. Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.

    The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity.

    Time frame: Up to approximately 6 months

  9. Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.

    Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe.

    Time frame: Up to approximately 6 months

  10. Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire

    The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse.

    Time frame: Up to approximately 6 months

  11. Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.

    The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse.

    Time frame: Up to approximately 6 months

Other outcomes

  1. Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.

    Measured by dedicated questionnaire.

    Time frame: Up to approximately 6 months

  2. Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12

    The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\] with the exception of Question 1 score ranging from 0 \[very often\] to 4 \[never\]).

    Time frame: Up to approximately 6 months

  3. Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale

    The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy).

    Time frame: Up to approximately 6 months

  4. Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)

    Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident.

    Time frame: Up to approximately 6 months

  5. Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale

    The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living.

    Time frame: Up to approximately 6 months

  6. Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)

    Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options.

    Time frame: Up to approximately 6 months

  7. Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index

    The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

    Time frame: Up to approximately 6 months

  8. Healthcare Resource Utilization (HRU)

    Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists.

    Time frame: Up to approximately 6 months

  9. Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)

    Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6

    Time frame: Up to approximately 6 months

  10. Questionnaire to investigate the practicalities of the infusion system

    Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments).

    Time frame: Up to approximately 6 months

  11. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 6 months

07

Study locations

26 of 26 sites recruiting
  • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190
    Boca Raton, Florida 33486, United States
    Recruiting
  • University of South Florida- Neuroscience Institute /ID# 278562
    Tampa, Florida 33613, United States
    Recruiting
  • Novant Health /ID# 278567
    Charlotte, North Carolina 28207-1196, United States
    Recruiting
  • Texas Movement Disorder Specialists /ID# 278565
    Georgetown, Texas 78628, United States
    Recruiting
  • Toronto Western Hospital /ID# 278384
    Toronto, Ontario M5T 2S8, Canada
    Recruiting
  • CIUSSS de l Estrie - CHUS /ID# 278379
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
  • Klinicka Bolnica Dubrava /ID# 278408
    Grad Zagreb, City of Zagreb 10000, Croatia
    Recruiting
  • Klinicki Bolnicki Centar Rijeka /ID# 278277
    Rijeka, Primorje-Gorski Kotar County 51000, Croatia
    Recruiting
  • Shaare Zedek Medical Center /ID# 276209
    Jerusalem, Jerusalem 91031, Israel
    Recruiting
  • The Chaim Sheba Medical Center /ID# 276210
    Ramat Gan, Tel Aviv 5265601, Israel
    Recruiting
  • Tel Aviv Sourasky Medical Center /ID# 276212
    Tel Aviv, Tel Aviv 6423906, Israel
    Recruiting
  • Hadassah Medical Center-Hebrew University /ID# 276211
    Jerusalem, 91120, Israel
    Recruiting
  • Saitama Medical University Hospital /ID# 280624
    Iruma-gun, Saitama 3500495, Japan
    Recruiting
  • Juntendo University Hospital /ID# 280623
    Bunkyo-ku, Tokyo 113-8431, Japan
    Recruiting
  • Noge General Medicine and Neurology /ID# 280741
    Kanagawa, 231-0063, Japan
    Recruiting
  • Itsuki Hospital /ID# 280743
    Tokushima, 770-0852, Japan
    Recruiting
  • Miwa Internal Medicine Clinic /ID# 280740
    Tokyo, 202-0004, Japan
    Recruiting
  • Centro Internacional De Mercadeo /ID# 276088
    Guaynabo, 00969, Puerto Rico
    Recruiting
  • Fundeni Clinical Institute /ID# 277490
    Bucharest, Bucharest 022328, Romania
    Recruiting
  • Arcadia Spitale Si Centre Medicale /Id# 277525
    Iași, Iaşi 700620, Romania
    Recruiting
  • Neurotim Med /ID# 277500
    Timișoara, Timiș County 300724, Romania
    Recruiting
  • Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499
    Brasov, 500326, Romania
    Recruiting
  • Hospital de Sant Joan Despi Moises Broggi /ID# 276895
    Sant Joan Despí, Barcelona 08970, Spain
    Recruiting
  • University Hospitals Plymouth NHS Trust /ID# 284977
    Plymouth, Devon PL6 8DH, United Kingdom
    Recruiting
  • Charing Cross Hospital /ID# 284211
    London, Hammersmith and Fulham W6 8RF, United Kingdom
    Recruiting
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752
    Newcastle upon Tyne, NE3 3HD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 14 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2025
First posted
Nov 13, 2025
StartActual
Aug 3, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added — first sites in Canada, Croatia, Japan, Puerto Rico and Spain. Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499 is now Recruiting
Show 16 added (5 Japan, 3 United States, 2 Canada, 2 Croatia, 2 United Kingdom, 1 Puerto Rico, 1 Spain)
  • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190 · Boca Raton, United States
  • University of South Florida- Neuroscience Institute /ID# 278562 · Tampa, United States
  • Novant Health /ID# 278567 · Charlotte, United States
  • Toronto Western Hospital /ID# 278384 · Toronto, Canada
  • CIUSSS de l Estrie - CHUS /ID# 278379 · Sherbrooke, Canada
  • Klinicka Bolnica Dubrava /ID# 278408 · Grad Zagreb, Croatia
  • Klinicki Bolnicki Centar Rijeka /ID# 278277 · Rijeka, Croatia
  • Saitama Medical University Hospital /ID# 280624 · Iruma-gun, Japan
  • Juntendo University Hospital /ID# 280623 · Bunkyo-ku, Japan
  • Noge General Medicine and Neurology /ID# 280741 · Kanagawa, Japan
  • Itsuki Hospital /ID# 280743 · Tokushima, Japan
  • Miwa Internal Medicine Clinic /ID# 280740 · Tokyo, Japan
  • Centro Internacional De Mercadeo /ID# 276088 · Guaynabo, Puerto Rico
  • Hospital de Sant Joan Despi Moises Broggi /ID# 276895 · Sant Joan Despí, Spain
  • Charing Cross Hospital /ID# 284211 · London, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752 · Newcastle upon Tyne, United Kingdom
Nov 10, 2026
Eligibility
Maximum age 80 Years→69 Years; 3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAdult male or female between 18 and 8069 years of age
  • EditedTime since motor fluctuations started ≤35 years
  • Edited"off" time of 2≤ 4.5-6 hours per day
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline in OFF Time (hours)motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscoreTime frame: Up to approximately 6 months
Nov 10, 2026
Secondary outcomes
10 edited, 2 added, 3 description edited
What changed in the outcomes
  • EditedChange From Baseline in Dyskinesia presenceto "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scoresTime frame: Up to approximately 6 months
  • EditedChange From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 scoreTime frame: Up to approximately 6 months
  • EditedChange From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.Time frame: Up to approximately 6 months
  • EditedChange From Baseline in Clinician-Reported Symptom severitySeverity measured by the PatientClinical Global Impression of ChangeSeverity (PGICGI-CS) questionnaire.Time frame: Up to approximately 6 months
  • EditedChange From Baseline in Patient-Reported Symptom severityChange measured by the ClinicalPatient Global Impression of SeverityChange (CGIPGI-SC) scoresquestionnaireTime frame: Up to approximately 6 months
  • EditedChange From Baseline in Clinician-Reported Symptom severityChange measured by the Clinical Global Impression of Change (CGI-C) scoresquestionnaire.Time frame: Up to approximately 6 months
  • ChangedBefore Change From Baseline in Motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IVNow Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total scoreTime frame: Up to approximately 6 months
  • Editedother outcomeChange From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living Scale (SE-ADL) ScaleTime frame: Up to approximately 6 months
  • Editedother outcomeChange From Baseline in Ability to reintegrate into normal social activity after illnessReintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) ScaleTime frame: Up to approximately 6 months
  • Editedother outcomeNumber of Participants who used Healthcare Resource Utilization (HRU)Time frame: Up to approximately 6 months
  • Addedother outcomeChange From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12Time frame: Up to approximately 6 months
  • Addedother outcomeNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately 6 months
  • Descriptionother outcomeChange From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD): how it is measured was reworded
  • Descriptionother outcomeChange From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9): how it is measured was reworded
  • Descriptionother outcomeQuestionnaire to investigate the practicalities of the infusion system: how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    16 sites added — first sites in Canada, Croatia, Japan, Puerto Rico and Spain. Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499 is now Recruiting
    Show 16 added (5 Japan, 3 United States, 2 Canada, 2 Croatia, 2 United Kingdom, 1 Puerto Rico, 1 Spain)
    • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190 · Boca Raton, United States
    • University of South Florida- Neuroscience Institute /ID# 278562 · Tampa, United States
    • Novant Health /ID# 278567 · Charlotte, United States
    • Toronto Western Hospital /ID# 278384 · Toronto, Canada
    • CIUSSS de l Estrie - CHUS /ID# 278379 · Sherbrooke, Canada
    • Klinicka Bolnica Dubrava /ID# 278408 · Grad Zagreb, Croatia
    • Klinicki Bolnicki Centar Rijeka /ID# 278277 · Rijeka, Croatia
    • Saitama Medical University Hospital /ID# 280624 · Iruma-gun, Japan
    • Juntendo University Hospital /ID# 280623 · Bunkyo-ku, Japan
    • Noge General Medicine and Neurology /ID# 280741 · Kanagawa, Japan
    • Itsuki Hospital /ID# 280743 · Tokushima, Japan
    • Miwa Internal Medicine Clinic /ID# 280740 · Tokyo, Japan
    • Centro Internacional De Mercadeo /ID# 276088 · Guaynabo, Puerto Rico
    • Hospital de Sant Joan Despi Moises Broggi /ID# 276895 · Sant Joan Despí, Spain
    • Charing Cross Hospital /ID# 284211 · London, United Kingdom
    • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752 · Newcastle upon Tyne, United Kingdom
    Eligibility Maximum age 80 Years→69 Years; 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdult male or female between 18 and 8069 years of age
    • EditedTime since motor fluctuations started ≤35 years
    • Edited"off" time of 2≤ 4.5-6 hours per day
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline in OFF Time (hours)motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscoreTime frame: Up to approximately 6 months
    Secondary outcomes 10 edited, 2 added, 3 description edited
    What changed in the outcomes
    • EditedChange From Baseline in Dyskinesia presenceto "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scoresTime frame: Up to approximately 6 months
    • EditedChange From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 scoreTime frame: Up to approximately 6 months
    • EditedChange From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.Time frame: Up to approximately 6 months
    • EditedChange From Baseline in Clinician-Reported Symptom severitySeverity measured by the PatientClinical Global Impression of ChangeSeverity (PGICGI-CS) questionnaire.Time frame: Up to approximately 6 months
    • EditedChange From Baseline in Patient-Reported Symptom severityChange measured by the ClinicalPatient Global Impression of SeverityChange (CGIPGI-SC) scoresquestionnaireTime frame: Up to approximately 6 months
    • EditedChange From Baseline in Clinician-Reported Symptom severityChange measured by the Clinical Global Impression of Change (CGI-C) scoresquestionnaire.Time frame: Up to approximately 6 months
    • ChangedBefore Change From Baseline in Motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IVNow Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total scoreTime frame: Up to approximately 6 months
    • Editedother outcomeChange From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living Scale (SE-ADL) ScaleTime frame: Up to approximately 6 months
    • Editedother outcomeChange From Baseline in Ability to reintegrate into normal social activity after illnessReintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) ScaleTime frame: Up to approximately 6 months
    • Editedother outcomeNumber of Participants who used Healthcare Resource Utilization (HRU)Time frame: Up to approximately 6 months
    • Addedother outcomeChange From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12Time frame: Up to approximately 6 months
    • Addedother outcomeNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately 6 months
    • Descriptionother outcomeChange From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD): how it is measured was reworded
    • Descriptionother outcomeChange From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9): how it is measured was reworded
    • Descriptionother outcomeQuestionnaire to investigate the practicalities of the infusion system: how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07227896
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
Aug 3, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Lars Bergmann
Contact
lars.bergmann@abbvie.com
+49(0)170 4538568
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion